少なくとも2種類の治療を受けた原発性免疫性血小板減少症(ITP)患者を対象としたイアナルマブ(VAY736)の第2相試験
少なくともコルチコステロイドとトロンボポエチン受容体アゴニスト(TPO-RA)による治療歴のある原発性免疫性血小板減少症(ITP)患者を対象としたイアナルマブ(VAY736)の有効性と安全性を評価する第2相試験
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.
調査の概要
詳細な説明
This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count <30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.
The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.
研究の種類
入学 (実際)
段階
- フェーズ2
アクセスの拡大
連絡先と場所
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
Boston、Massachusetts、アメリカ、02215
- Beth Israel Deaconess Med Center
-
-
-
-
-
CABA、アルゼンチン、C1181ACH
- Novartis Investigative Site
-
-
-
-
-
Glasgow、イギリス、G31 2ER
- Novartis Investigative Site
-
London、イギリス、W12 0HS
- Novartis Investigative Site
-
-
-
-
TO
-
Torino、TO、イタリア、10126
- Novartis Investigative Site
-
-
-
-
Australian Capital Territory
-
Garran、Australian Capital Territory、オーストラリア、2605
- Novartis Investigative Site
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3004
- Novartis Investigative Site
-
-
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、08003
- Novartis Investigative Site
-
-
-
-
-
Izmir、トルコ(Türkiye)、35100
- Novartis Investigative Site
-
Kocaeli、トルコ(Türkiye)、41380
- Novartis Investigative Site
-
-
Efeler
-
Aydin、Efeler、トルコ(Türkiye)、09100
- Novartis Investigative Site
-
-
Fatih
-
Istanbul、Fatih、トルコ(Türkiye)、34098
- Novartis Investigative Site
-
-
Merkez
-
Edirne、Merkez、トルコ(Türkiye)、22030
- Novartis Investigative Site
-
-
-
-
-
Giessen、ドイツ、35392
- Novartis Investigative Site
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- Novartis Investigative Site
-
-
Thuringia
-
Jena、Thuringia、ドイツ、07740
- Novartis Investigative Site
-
-
-
-
-
Toulouse、フランス、31059
- Novartis Investigative Site
-
-
-
-
-
Katowice、ポーランド、40-519
- Novartis Investigative Site
-
-
-
-
-
Johor Bahru、マレーシア、80100
- Novartis Investigative Site
-
-
-
-
-
Beijing、中国、100730
- Novartis Investigative Site
-
Jinan、中国、250012
- Novartis Investigative Site
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Novartis Investigative Site
-
-
-
-
-
Seoul、韓国、06591
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Signed informed consent obtained prior to participation in the study.
-
Male or female participants aged 18 years and older on the day of signing informed consent.
-
Confirmed diagnosis of primary ITP.
- Prior treatment with at least a corticosteroid (±IVIG) and a TPO-RA:
- Prior additional therapies are allowed; the corticosteroid or the TPO-RA do not need to be the last treatment.
- Prior response to IVIG/anti-D or a corticosteroid (platelet count ≥50 G/L) that was not maintained.
-
At last ITP treatment, loss of response, insufficient response, no response or intolerance.
-
Platelet count <30 G/L and assessed as needing treatment (per physician's discretion) at screening. If concomitant ITP medication is clinically indicated, the platelet assessment showing a value <30 G/L must be performed after at least 14 days on a stable dose of a corticosteroid or/and a TPO-RA (less than 10% variation from current dose) and continue stable thereafter.
Key exclusion criteria:
-
Diagnosis of secondary thrombocytopenia.
-
Platelet or whole blood transfusion, plasmapheresis, or use of any other rescue medications within 14 days before first ianalumab infusion.
-
Participants with the following conditions at screening:
- Neutrophils <1000/mm3.
- Immunoglobulin G (IgG) <5 g/L
-
Treatment with a B-cell depleting therapy (e.g., rituximab) or anti-B-cell Activating Factor of the TNF Family (BAFF) (e.g., belimumab) within 12 weeks prior to the first administration of ianalumab.
-
Immunosuppressant drugs other than corticosteroids within 5 times the elimination half-life of the drug or 14 days before first ianalumab infusion, whichever is longer.
-
Prior splenectomy.
Other protocol-defined inclusion/exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single-arm
All eligible participants will receive ianalumab at the same dose. |
Intravenous infusion, prepared from concentrate solution
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Confirmed response
時間枠:Between Week 1 Day 1 and Week 25 Day 1
|
Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:
|
Between Week 1 Day 1 and Week 25 Day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to confirmed response
時間枠:From Week 1 Day 1 to Week 25 Day 1
|
Time from the first administration of ianalumab to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint. |
From Week 1 Day 1 to Week 25 Day 1
|
|
Duration of confirmed response
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Time from the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:
|
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Complete Response rate at each timepoint
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Response rate at each timepoint
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Stable response at 6 months
時間枠:At 6 months
|
Percentage of participants with at least 75% of platelet counts collected at month 6 (between study days 121 and 183) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment. |
At 6 months
|
|
Stable response at 1 year
時間枠:At 1 year
|
Percentage of participants with at least 66% of platelet counts collected at year 1 (between study days 296 and 379) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment. |
At 1 year
|
|
Bleeding events according to the Modified World Health Organization (WHO) bleeding scale
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Number of participants who received rescue treatment
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Number of participants who required rescue treatment |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Percentage of participants who received rescue treatment
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants who required rescue treatment |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from baseline in the frequency of CD19+ B-cell counts
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline frequency of CD19+ B-cell counts compared to baseline |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from baseline in the absolute number of CD19+ B-cell counts
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from baseline in immunoglobulins
時間枠:From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to baseline |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
時間枠:Up to 20 weeks after last dose of ianalumab
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab |
Up to 20 weeks after last dose of ianalumab
|
|
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
時間枠:Up to 20 weeks after last dose of ianalumab
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab |
Up to 20 weeks after last dose of ianalumab
|
|
Ianalumab serum concentrations over time
時間枠:First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Ianalumab concentration in serum over time, including end of infusion and concentration at trough. |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Ianalumab serum PK: AUC concentrations over time
時間枠:First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Ianalumab concentration in serum over time, including end of infusion and concentration at trough. |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Ianalumab serum PK parameters: Cmax
時間枠:First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Ianalumab serum PK parameters: Tmax
時間枠:First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Confirmed response (CR) in the second course
時間枠:Second course Week 1 Day1 to second course Week 25 Day1
|
Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:
|
Second course Week 1 Day1 to second course Week 25 Day1
|
|
Time to confirmed response in the second course
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
two (or more) platelet assessments meeting the criteria of a confirmed response. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Duration of confirmed response in the second course
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Time from the first assessment, in the second course of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:
|
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Response in the second course
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Complete Response in the second course
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Bleeding events in the second course according to the Modified World Health Organization (WHO) bleeding scale
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Percentage of participants with bleeding events in the retreatment/second courseaccording to the Modified World Health Organization (WHO) bleeding scale
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Number of Participants who received rescue treatment after second course
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Number of participants who required rescue treatment |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Percentage of participants who received rescue treatment after receiving second course
時間枠:Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants who required rescue treatment |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Titer of anti-ianalumab antibodies in serum (ADA assay) over time for second course
時間枠:Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab |
Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
|
|
Change from start of second course in immunoglobulins
時間枠:From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to retreatment baseline |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from start of second course in the absolute number of CD19+ B-cell counts
時間枠:From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from start of second course to end of study in the absolute number of CD19+ B-cell counts
時間枠:From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
時間枠:From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Ianalumab serum concentrations over time in the second course
時間枠:First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course
|
Ianalumab concentration in serum over time, including end of infusion and concentration at trough. |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CVAY736Q12201
- 2022-503041-21-00 (その他の識別子:EU CTIS)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。